From: Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy
Dose level
Number of patients treated
Azacitidine (mg/m 2 )
Oxaliplatin IV (mg/m 2 /day)
DLT
1
3
20
15
0
2
22.5
30
4
25
5
40
6
50
Expansion (dose level 6)
16